Skip to main content

Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.

Publication ,  Journal Article
Rahman, SN; Long, JB; Westvold, SJ; Leapman, MS; Spees, LP; Hurwitz, ME; McManus, HD; Gross, CP; Wheeler, SB; Dinan, MA
Published in: JAMA Netw Open
April 1, 2024

IMPORTANCE: Area-level measures of sociodemographic disadvantage may be associated with racial and ethnic disparities with respect to receipt of treatment for metastatic renal cell carcinoma (mRCC) but have not been investigated previously, to our knowledge. OBJECTIVE: To assess the association between area-level measures of social vulnerability and racial and ethnic disparities in the treatment of US Medicare beneficiaries with mRCC from 2015 through 2019. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included Medicare beneficiaries older than 65 years who were diagnosed with mRCC from January 2015 through December 2019 and were enrolled in fee-for-service Medicare Parts A, B, and D from 1 year before through 1 year after presumed diagnosis or until death. Data were analyzed from November 22, 2022, through January 26, 2024. EXPOSURES: Five different county-level measures of disadvantage and 4 zip code-level measures of vulnerability or deprivation and segregation were used to dichotomize whether an individual resided in the most vulnerable quartile according to each metric. Patient-level factors included age, race and ethnicity, sex, diagnosis year, comorbidities, frailty, Medicare and Medicaid dual enrollment eligibility, and Medicare Part D low-income subsidy (LIS). MAIN OUTCOMES AND MEASURES: The main outcomes were receipt and type of systemic therapy (oral anticancer agent or immunotherapy from 2 months before to 1 year after diagnosis of mRCC) as a function of patient and area-level characteristics. Multivariable regression analyses were used to adjust for patient factors, and odds ratios (ORs) from logistic regression and relative risk ratios (RRRs) from multinomial logistic regression are reported. RESULTS: The sample included 15 407 patients (mean [SD] age, 75.6 [6.8] years), of whom 9360 (60.8%) were men; 6931 (45.0%), older than 75 years; 93 (0.6%), American Indian or Alaska Native; 257 (1.7%), Asian or Pacific Islander; 757 (4.9%), Hispanic; 1017 (6.6%), non-Hispanic Black; 12 966 (84.2%), non-Hispanic White; 121 (0.8%), other; and 196 (1.3%), unknown. Overall, 8317 patients (54.0%) received some type of systemic therapy. After adjusting for individual factors, no county or zip code-level measures of social vulnerability, deprivation, or segregation were associated with disparities in treatment. In contrast, patient-level factors, including female sex (OR, 0.78; 95% CI, 0.73-0.84) and LIS (OR, 0.48; 95% CI, 0.36-0.65), were associated with lack of treatment, with particularly limited access to immunotherapy for patients with LIS (RRR, 0.25; 95% CI, 0.14-0.43). Associations between individual-level factors and treatment in multivariable analysis were not mediated by the addition of area-level metrics. Disparities by race and ethnicity were consistently and only observed within the most vulnerable areas, as indicated by the top quartile of each vulnerability deprivation index. CONCLUSIONS AND RELEVANCE: In this cohort study of older Medicare patients diagnosed with mRCC, individual-level demographics, including race and ethnicity, sex, and income, were associated with receipt of systemic therapy, whereas area-level measures were not. However, individual-level racial and ethnic disparities were largely limited to socially vulnerable areas, suggesting that efforts to improve racial and ethnic disparities may be most effective when targeted to socially vulnerable areas.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Netw Open

DOI

EISSN

2574-3805

Publication Date

April 1, 2024

Volume

7

Issue

4

Start / End Page

e248747

Location

United States

Related Subject Headings

  • Vulnerable Populations
  • United States
  • Socioeconomic Factors
  • Social Vulnerability
  • Retrospective Studies
  • Medicare
  • Male
  • Kidney Neoplasms
  • Humans
  • Healthcare Disparities
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rahman, S. N., Long, J. B., Westvold, S. J., Leapman, M. S., Spees, L. P., Hurwitz, M. E., … Dinan, M. A. (2024). Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open, 7(4), e248747. https://doi.org/10.1001/jamanetworkopen.2024.8747
Rahman, Syed N., Jessica B. Long, Sarah J. Westvold, Michael S. Leapman, Lisa P. Spees, Michael E. Hurwitz, Hannah D. McManus, Cary P. Gross, Stephanie B. Wheeler, and Michaela A. Dinan. “Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.JAMA Netw Open 7, no. 4 (April 1, 2024): e248747. https://doi.org/10.1001/jamanetworkopen.2024.8747.
Rahman SN, Long JB, Westvold SJ, Leapman MS, Spees LP, Hurwitz ME, et al. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2024 Apr 1;7(4):e248747.
Rahman, Syed N., et al. “Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.JAMA Netw Open, vol. 7, no. 4, Apr. 2024, p. e248747. Pubmed, doi:10.1001/jamanetworkopen.2024.8747.
Rahman SN, Long JB, Westvold SJ, Leapman MS, Spees LP, Hurwitz ME, McManus HD, Gross CP, Wheeler SB, Dinan MA. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2024 Apr 1;7(4):e248747.

Published In

JAMA Netw Open

DOI

EISSN

2574-3805

Publication Date

April 1, 2024

Volume

7

Issue

4

Start / End Page

e248747

Location

United States

Related Subject Headings

  • Vulnerable Populations
  • United States
  • Socioeconomic Factors
  • Social Vulnerability
  • Retrospective Studies
  • Medicare
  • Male
  • Kidney Neoplasms
  • Humans
  • Healthcare Disparities